Study of sacituzumab tirumotecan for advanced thymic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new targeted drug (sacituzumab tirumotecan) for people with advanced thymic cancer that has gotten worse after at least one prior treatment. The goal is to see if the drug can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced thymic cancer that cannot be removed by surgery or has spread to other parts of the body.
- Your cancer has gotten worse after at least one prior treatment (chemotherapy or immunotherapy).
- You have at least one measurable tumor.
- You are over 18 years old and in relatively good health (able to perform daily activities without assistance).
- You have adequate organ function (bone marrow, kidney, liver, and heart).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
This study tests a new drug called sacituzumab tirumotecan for people with thymic carcinoma that has spread or come back after platinum-based chemotherapy. The drug targets a protein on cancer cells to deliver chemotherapy directly to them, which may help shrink tumors or slow their growth.
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
This trial tests a new targeted drug, sacituzumab tirumotecan, for people with advanced small bowel adenocarcinoma that has not responded to or cannot tolerate platinum-based chemotherapy. The drug targets a protein called TROP2 on cancer cells to deliver treatment directly to them.
This study tests a new combination of drugs (sacituzumab tirumotecan plus others) for people with advanced esophageal squamous cell carcinoma. It aims to see if the combination works better for those who have not had treatment before or whose cancer progressed after one line of therapy.
This trial tests a new drug, sacituzumab tirumotecan, for people with advanced biliary tract cancer that has stopped responding to previous treatments. It works by targeting a protein called TROP2 on cancer cells. This may be an option if your cancer has progressed and you meet the health criteria.
Hear when a new Thymic Epithelial Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.